Santillan Antonio, Karam Amer K, Li Andrew J, Giuntoli Robert, Gardner Ginger J, Cass Ilana, Karlan Beth Y, Bristow Robert E
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, 600 N. Wolfe Street, Phipps #281, Baltimore, MD 21287-1281, USA.
Gynecol Oncol. 2007 Mar;104(3):686-90. doi: 10.1016/j.ygyno.2006.10.020. Epub 2006 Dec 1.
To evaluate the feasibility and associated survival outcome of secondary cytoreductive surgery in patients with isolated lymph node recurrence of epithelial ovarian cancer.
Twenty-five patients with epithelial ovarian cancer who underwent secondary cytoreductive surgery for isolated lymph node recurrence were identified from tumor registry databases. Demographic, diagnostic, operative, pathologic, and follow-up data were abstracted retrospectively. Overall survival was calculated using the Kaplan-Meier method.
The median age at time of primary surgery for ovarian cancer was 55 years; 72% of patients had FIGO III/IV disease, and all had high-grade tumors. All patients received platinum-based chemotherapy following primary surgery. The median time from completion of primary chemotherapy to nodal recurrence surgery was 16 months (range=6 to 40 months). The distribution of nodal involvement was pelvic=12% (n=3), para-aortic=60% (n=15), inguinal=20% (n=5), peri-cardiac=4% (n=1), and pelvic plus para-aortic=4% (n=1). The maximal nodal tumor diameter ranged from 1.5 cm to 14 cm, with a median of 3.0 cm. Optimal secondary cytoreductive surgery (residual disease </=1 cm) was achieved in 100% of patients. The median estimated intra-operative blood loss was 100 cc (range=10 cc to 600 cc). The length of hospitalization ranged from 2 days to 10 days, with a median of 4 days. There was no instance significant postoperative morbidity. At a median post-recurrence follow-up time of 19 months, 8 patients (32%) have died of the disease, 7 (28%) are alive with disease, and 10 (40%) patients are without evidence of disease. For the entire study population, the median post-recurrence OS after secondary cytoreduction of recurrent nodal disease was 37 months.
Complete optimal secondary cytoreductive surgery for recurrent epithelial ovarian cancer presenting as isolated node metastases is achievable in the majority of cases and is associated with a favorable long-term survival outcome.
评估上皮性卵巢癌孤立性淋巴结复发患者进行二次肿瘤细胞减灭术的可行性及相关生存结局。
从肿瘤登记数据库中确定25例因孤立性淋巴结复发而接受二次肿瘤细胞减灭术的上皮性卵巢癌患者。回顾性提取人口统计学、诊断、手术、病理及随访数据。采用Kaplan-Meier法计算总生存期。
卵巢癌初次手术时的中位年龄为55岁;72%的患者为国际妇产科联盟(FIGO)III/IV期疾病,且均为高级别肿瘤。所有患者在初次手术后均接受了铂类化疗。从初次化疗结束至淋巴结复发手术的中位时间为16个月(范围=6至40个月)。淋巴结受累分布情况为:盆腔12%(n=3)、腹主动脉旁60%(n=15)、腹股沟20%(n=5)(n=1)、心周4%(n=1)、盆腔加腹主动脉旁4%(n=1)。最大淋巴结肿瘤直径为1.5 cm至14 cm,中位值为3.0 cm。100%的患者实现了最佳二次肿瘤细胞减灭术(残留病灶≤1 cm)。术中估计失血量中位数为100 cc(范围=10 cc至600 cc)。住院时间为2天至10天,中位值为4天。无明显术后并发症发生。复发后中位随访时间为19个月时,8例(32%)患者死于该疾病,7例(28%)患者带瘤生存,10例(40%)患者无疾病证据。对于整个研究人群,复发性淋巴结疾病二次肿瘤细胞减灭术后复发后的中位总生存期为37个月。
对于表现为孤立性淋巴结转移的复发性上皮性卵巢癌,大多数病例可实现完全最佳的二次肿瘤细胞减灭术,且与良好的长期生存结局相关。